We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?
Read MoreHide Full Article
We expect investors to focus on Unum Therapeutics Inc.’s development plans for its preclinical candidate, BOXR1030, when it reports first-quarter 2020 earnings results.
The company’s performance over the last four quarters has been mixed with two estimate misses and two earnings beats, the average positive surprise being 20.30%. In the last reported quarter, Unum Therapeutics delivered a positive earnings surprise of 120.00%.
Shares of Unum Therapeutics have plunged 44.5% so far this year against the industry’s increase of 3%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Unum Therapeutics is focused on developing curative cell therapies for treating patients with solid tumor cancers. With no marketed products, the company only generates revenues from collaborations.
Unum Therapeutics had a collaboration agreement with Seattle Genetics for developing two novel antibody-coupled ACTR therapies using the latter’s proprietary antibodies. In January 2020, the collaboration agreement between the companies was terminated.
In March 2020, Unum Therapeutics announced plans to reduce its current workforce by approximately 60% to focus on the BOXR1030 program and BOXR platform. The company plans to file an investigational new drug (IND) application for initiating a clinical study on BOXR1030 later in 2020 to treat solid tumor cancers. BOXR103 is currently in pre-clinical studies.
Activities related to the development of BOXR1030 are likely to have escalated operating expense in the to-be-reported quarter.
Meanwhile, as part of its prioritization toward BOXR1030 and BOXR platform, Unum Therapeutics is looking to close its clinical studies on its lead hematologic candidate ACTR707. The company is concluding two phase I studies on ACTR707. One study evaluated the candidate in combination with Roche’s Rituxan (rituximab) for treating adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL), the other evaluated the same in combination with Roche’s Herceptin (trastuzumab) for advanced HER2+ solid tumor cancers. Earlier, the company had announced plans to conclude clinical studies on ACTR087.
Unum Therapeutics expects to end these early-stage studies during the remainder of this year and by early 2021.
We expect management to update the same on the first-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Unum Therapeutics this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But this is not the case here.
Earnings ESP: Unum Therapeutics has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 33 cents per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Unum Therapeutics sports a Zacks Rank #1, which increases the predictive power of ESP. However, its 0.00% ESP makes surprise prediction difficult.
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) has an Earnings ESP of +4.44% and a Zacks Rank of 3. The company is scheduled to release results on May 6.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?
We expect investors to focus on Unum Therapeutics Inc.’s development plans for its preclinical candidate, BOXR1030, when it reports first-quarter 2020 earnings results.
The company’s performance over the last four quarters has been mixed with two estimate misses and two earnings beats, the average positive surprise being 20.30%. In the last reported quarter, Unum Therapeutics delivered a positive earnings surprise of 120.00%.
Shares of Unum Therapeutics have plunged 44.5% so far this year against the industry’s increase of 3%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Unum Therapeutics is focused on developing curative cell therapies for treating patients with solid tumor cancers. With no marketed products, the company only generates revenues from collaborations.
Unum Therapeutics had a collaboration agreement with Seattle Genetics for developing two novel antibody-coupled ACTR therapies using the latter’s proprietary antibodies. In January 2020, the collaboration agreement between the companies was terminated.
In March 2020, Unum Therapeutics announced plans to reduce its current workforce by approximately 60% to focus on the BOXR1030 program and BOXR platform. The company plans to file an investigational new drug (IND) application for initiating a clinical study on BOXR1030 later in 2020 to treat solid tumor cancers. BOXR103 is currently in pre-clinical studies.
Activities related to the development of BOXR1030 are likely to have escalated operating expense in the to-be-reported quarter.
Meanwhile, as part of its prioritization toward BOXR1030 and BOXR platform, Unum Therapeutics is looking to close its clinical studies on its lead hematologic candidate ACTR707. The company is concluding two phase I studies on ACTR707. One study evaluated the candidate in combination with Roche’s Rituxan (rituximab) for treating adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL), the other evaluated the same in combination with Roche’s Herceptin (trastuzumab) for advanced HER2+ solid tumor cancers. Earlier, the company had announced plans to conclude clinical studies on ACTR087.
Unum Therapeutics expects to end these early-stage studies during the remainder of this year and by early 2021.
We expect management to update the same on the first-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Unum Therapeutics this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But this is not the case here.
Earnings ESP: Unum Therapeutics has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 33 cents per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Unum Therapeutics sports a Zacks Rank #1, which increases the predictive power of ESP. However, its 0.00% ESP makes surprise prediction difficult.
Unum Therapeutics Inc. Price and EPS Surprise
Unum Therapeutics Inc. price-eps-surprise | Unum Therapeutics Inc. Quote
Stocks to Consider
Here are some biotech stocks that have the right combination of elements to beat on earnings this time around:
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +2.28% and a Zacks Rank #2. The company is scheduled to release results on May 6. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) has an Earnings ESP of +4.44% and a Zacks Rank of 3. The company is scheduled to release results on May 6.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>